GenMark Diagnostics, which offers a molecular diagnostics testing system to hospitals and labs, raised $28 million by offering 4.6 million shares at $6, the low end of the revised $6-$7 range. The company had originally planned to sell 4.5 million shares at a range of $8-$10. GenMark Diagnostics listed on the NASDAQ under the symbol GNMK Friday afternoon; Piper Jaffray acted as lead manager on the deal.
